- FDA CVM has accepted the Target Animal Safety (TAS) section of Loyal’s conditional approval application for LOY-002.
- LOY-002 has now cleared two of three major FDA technical sections, alongside Reasonable Expectation of Effectiveness (RXE).
- The drug is designed to extend healthy lifespan and preserve quality of life in senior dogs.
- Acceptance supports Loyal’s path toward Expanded Conditional Approval (XCA), a newer FDA regulatory pathway.
- Safety data included results from more than 400 dogs enrolled in Loyal’s STAY study.
- If approved, LOY-002 would be the first FDA-approved lifespan extension drug in any species.
Loyal, a clinical-stage animal health company focused on lifespan extension in dogs, announced that the FDA’s Center for Veterinary Medicine has accepted the Target Animal Safety (TAS) technical section of its conditional approval application for LOY-002. The acceptance marks a significant step toward market launch for what could become the first FDA-approved drug intended specifically to extend lifespan.
With both the TAS and Reasonable Expectation of Effectiveness (RXE) sections now accepted by the FDA, LOY-002 has completed two of the three major technical components required for conditional approval. The company expects to complete the final section and apply for Expanded Conditional Approval (XCA) next year.
LOY-002 is a once-daily oral prescription drug designed for senior dogs. Rather than treating a single disease, the therapy targets underlying metabolic drivers of aging with the goal of delaying disease onset and maintaining quality of life as dogs grow older. If approved, the drug would represent a first-in-class regulatory decision for lifespan extension itself, not just age-related conditions.
Acceptance of the TAS submission reflects the FDA’s review of safety data from multiple studies, including a standard safety study and additional field safety data from more than 400 dogs enrolled in Loyal’s pivotal STAY trial. The FDA concluded that the submitted data support LOY-002’s safety under its proposed conditions of use.
“As a veterinarian, what I care about most, especially when it involves preventive care, is safety,” said Dr. Ellen Ratcliff, Loyal’s vice president of clinical and veterinary medicine. “The FDA’s sign-off on this submission is an important vote of confidence in our mission to develop safe and effective lifespan extension drugs for dogs.”
The milestone follows several advances for LOY-002 over the past year. The FDA accepted the RXE section of the application in February 2025, and Loyal completed enrollment for the STAY trial in July 2025. The study includes approximately 1,300 dogs across 70 veterinary clinics, making it the largest clinical trial conducted in veterinary medicine to date.
Founded six years ago, Loyal has raised more than $150 million to support its mission of extending canine lifespan and improving health during aging. The company currently has three longevity-focused drug programs in development and continues to work closely with the FDA’s Center for Veterinary Medicine toward approval.
Information sourced from the company’s press release.
